Bailey John, Gill Simon, Poole Rob
Centre for Mental Health and Society, Bangor University Wrexham Academic Unit, Technology Park Wrexham, Wrexham, UK
Betsi Cadwaladr University Health Board, North Wales, UK.
BJGP Open. 2022 Dec 20;6(4). doi: 10.3399/BJGPO.2021.0217. Print 2022 Dec.
Opioid prescriptions for chronic pain have risen sharply over the last 25 years; harms associated with these drugs are related to dose and length of use.
The main aim of this study was to identify patients prescribed long-term, high-dose (LTHD) opioids in the community and to assess the prevalence of such use.
DESIGN & SETTING: An observational study of opioid prescribing in two demographically dissimilar GP practices in North Wales, UK.
Details of opioid prescriptions were collected for 22 841 patients, of whom 1488 (6.5%) were being prescribed opioids on the census date. Exhaustive examination of the data identified all patients who were prescribed oral morphine equivalent doses of ≥120 mg/day for ≥1 year.
All these patients were being prescribed ≥120 mg/day, as a single drug, morphine, oxycodone, fentanyl, or buprenorphine, irrespective of opioid polypharmacy. Across both practices, 1.71/1000 patients were identified as LTHD users of opioid medication for chronic non-cancer pain (CNCP). Prevalence was similar in the two practices. Repetition of the process until January 2021 showed no change in the pattern.
This study offers confirmation that a significant group of patients are prescribed long-term opioid medication for chronic pain at doses that are unlikely to be effective in reducing pain, but are likely to have harmful consequences. The findings offer a simple, reliable, and practical method of data extraction to identify these patients individually from routinely collected prescribing data, which will help in monitoring and treating individuals and establishing the problem prevalence.
在过去25年中,用于慢性疼痛的阿片类药物处方量急剧上升;与这些药物相关的危害与剂量和使用时长有关。
本研究的主要目的是识别社区中开具长期、高剂量(LTHD)阿片类药物的患者,并评估此类使用的患病率。
对英国北威尔士两个人口统计学特征不同的全科医疗实践中阿片类药物处方进行的一项观察性研究。
收集了22841名患者的阿片类药物处方细节,其中1488名(6.5%)在普查日期正在接受阿片类药物治疗。对数据进行详尽检查,确定了所有开具口服吗啡等效剂量≥120毫克/天且持续≥1年的患者。
所有这些患者均被开具≥120毫克/天的单一药物,即吗啡、羟考酮、芬太尼或丁丙诺啡,无论是否使用多种阿片类药物。在这两个医疗实践中,1.71/1000的患者被确定为慢性非癌性疼痛(CNCP)的长期、高剂量阿片类药物使用者。两个医疗实践中的患病率相似。重复该过程直至2021年1月,模式未发生变化。
本研究证实,有相当一部分患者被开具用于慢性疼痛的长期阿片类药物,其剂量不太可能有效减轻疼痛,但可能会产生有害后果。这些发现提供了一种简单、可靠且实用的数据提取方法,可从常规收集的处方数据中单独识别这些患者,这将有助于对个体进行监测和治疗,并确定问题的患病率。